系统性硬化症相关间质性肺病:指南如何落地临床
本文综述系统性硬化症相关间质性肺病(SSc-ILD)的诊治证据,涉及40%至60%的SSc患者且为首位死因。所有指南均推荐霉酚酸酯、托珠单抗、利妥昔单抗、环磷酰胺和尼达尼布,但多数证据质量低,仅霉酚酸酯获强推荐。文章强调诊断时高分辨率CT筛查及高危因素患者再筛查,并监测进展性肺纤维化。
要点
- 所有SSc患者诊断时应用高分辨率CT筛查ILD。
- 具≥1项高危因素或出现生理/症状变化者需再筛查。
- 仅霉酚酸酯获强推荐,其余药物推荐有条件性。
核心结论
- SSc-ILD影响40%至60%的SSc患者且为首位死因。
- 近期指南均推荐霉酚酸酯、托珠单抗、利妥昔单抗、环磷酰胺和尼达尼布,但推荐条件性不同。
- 仅霉酚酸酯被强推荐用于SSc-ILD,多数治疗证据质量低。
研究设计与样本
- 综述综合SSc-ILD管理证据,聚焦将近期指南应用于实践。
- 检索范围未在摘要中报告。
主要发现
- 证据支持所有SSc患者诊断时用胸部高分辨率CT筛查ILD。
- 具≥1项高危因素(男性、黑人种族、高龄、弥漫性皮肤病变、高改良Rodnan皮肤评分、抗拓扑异构酶抗体阳性、核仁型抗核抗体、肺功能受损)或出现生理变化/新呼吸道症状者应再筛查。
- 已确诊SSc-ILD患者应密切监测进展性肺纤维化。
关键数值与推荐
- SSc-ILD影响40%至60%的SSc患者。
- 高危因素包括男性、黑人种族、高龄、弥漫性皮肤病变、高改良Rodnan皮肤评分、抗拓扑异构酶抗体阳性、核仁型抗核抗体、肺功能受损。
- 指南推荐霉酚酸酯、托珠单抗、利妥昔单抗、环磷酰胺和尼达尼布,仅霉酚酸酯为强推荐。
临床怎么用
- 诊断SSc时即行胸部高分辨率CT筛查ILD。
- 对具≥1项高危因素或出现生理/症状变化者再筛查。
- 确诊SSc-ILD后密切监测进展性肺纤维化。
- 治疗选择参考近期指南,注意推荐条件性差异。
局限性
- 多数治疗证据质量评为低。
- SSc-ILD管理仍存大量未解答问题。
- 近期指南对治疗观点存在差异甚至矛盾。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
TOPIC IMPORTANCE: Interstitial lung disease (ILD) affects 40% to 60% of patients with systemic sclerosis (SSc) and represents the leading cause of death. Although treatment options for SSc with ILD remain limited, randomized controlled trials have demonstrated the safety and efficacy of approved and unapproved therapies. However, numerous unanswered questions remain regarding management of SSc with ILD, and 3 recently published clinical practice guidelines highlight the complexity of treating this condition. These guidelines offer distinct and sometimes contrasting views on treatment of SSc with ILD, creating unique challenges for clinicians. The present review aimed to synthesize evidence regarding the management of SSc with ILD with a focus on how to apply the recent guidelines into practice, beginning with screening for disease and extending to the intricate decision-making surrounding treatment. REVIEW FINDINGS: Although an abundance of evidence supports screening all patients with SSc for ILD with high-resolution CT imaging of the chest at the time of diagnosis, emerging evidence underscores the importance of rescreening patients who possess ≥ 1 high-risk factors (male sex, Black race, advanced age, diffuse cutaneous disease, high modified Rodnan skin score, antitopoisomerase antibody positivity, nucleolar antinuclear antibodies, and impaired lung function) or if physiologic changes, new respiratory symptoms, or both attributable to ILD emerge. Patients with established SSc with ILD should be monitored closely for the development of progressive pulmonary fibrosis. The guidelines all recommended, with varying degrees of conditionality, treatment with mycophenolate, tocilizumab, rituximab, cyclophosphamide, and nintedanib. The quality of evidence was rated as low for most therapies, and the only therapy strongly recommended for SSc with ILD was mycophenolate. SUMMARY: This review provides a comprehensive appraisal of current approaches to the diagnosis and treatment of SSc with ILD. It also highlights gaps in knowledge and proposes future opportunities to develop a precision-guided approach to diagnosing and treating SSc with ILD.
引用
- Esposito AJ, Selvan KC, Richardson C, et al. Systemic Sclerosis-Associated Interstitial Lung Disease: What We Know and How to Incorporate Guidelines Into Clinical Practice. Chest. 2025. PMID: 41397518. doi:10.1016/j.chest.2025.11.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。